ClinicalTrials.gg
RecruitingNCT07608055DCP-NDMUpdated Sep 3, 2026

Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss After Pancreatectomy in Non-Diabetic Patients

An observational study in Pancreatectomy, Diabetes Mellitus Type 2 and Pancreatic Neoplasms, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
579
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy — 45 open to participants now, 61 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Italy.

Planned enrollment
48th of 99
579 · median 500
Started
2026
with 14 others
Observational
99 of 421
19 open now
Primary completion
2037-05
later than 60 of 60 live
Registered
409th of 421
by date

Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, this one is the 48th largest by planned enrollment of the 99 observational ones that give a count, is one of 15 that started in 2026, is one of 99 observational ones, reaches primary completion later than 60 of the 60 other live ones, and was the 409th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

45 of the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy are open now. Recruiting first, the newest first:

39 more — sign in →

All 45 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, or all of them as a file.
02

Study summary

This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time.

The study will include adults without diabetes before surgery who undergo pancreatic surgery as part of routine clinical care at Fondazione Policlinico Universitario A. Gemelli IRCCS.

Researchers will study whether participants develop diabetes after surgery and whether this risk changes according to the type of pancreatic resection.

Information from routine clinical care, metabolic tests, imaging, and pancreatic tissue samples collected during surgery may be used for research analyses.

Read the detailed description

This is a monocentric ambispective observational cohort study conducted at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. The study integrates retrospective, ambispective, and prospective cohorts of patients undergoing partial, near-total, or total pancreatectomy for benign or malignant pancreatic disease.

Pancreatectomy represents a unique human model to investigate the metabolic consequences of acute pancreatic mass loss and beta-cell reduction. However, substantial interindividual variability exists in postoperative glycemic trajectories, suggesting that preoperative metabolic status and tissue-specific factors may contribute to the risk of new-onset diabetes after surgery.

The primary objective is to evaluate the incidence of new-onset diabetes mellitus within 12 months after surgery according to the type of pancreatic resection in patients without diabetes at baseline.

Secondary objectives include longitudinal evaluation of glycemic and metabolic changes after pancreatectomy, assessment of associations between preoperative metabolic characteristics and postoperative glycemic outcomes, exploratory evaluation of pancreatic tissue morphology/molecular characteristics, and analysis of oncologic outcomes including overall survival and disease-free survival.

Clinical, biochemical, radiologic, and metabolic data will be collected according to routine clinical practice. Metabolic evaluations may include OGTT, mixed meal test (MMT), and metabolic clamp procedures when available. Morphological and molecular analyses will be performed on pancreatic tissue obtained from surgical specimens in selected subgroups.

03

Conditions studied

  • Pancreatectomy
  • Diabetes Mellitus Type 2
  • Pancreatic Neoplasms

Keywords

  • Pancreatectomy
  • New-Onset Diabetes
  • Pancreatic Surgery
  • Beta-Cell Function
  • type 2 diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients without diabetes at baseline undergoing partial, near-total, or total pancreatectomy according to routine clinical practice for benign or malignant pancreatic diseases at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, including retrospective, ambispective, and prospective study components.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years)
  • No diabetes mellitus at baseline
  • Undergoing partial, near-total, or total pancreatectomy at the study center
  • Availability of clinical and metabolic data according to study component
  • Written for the prospective component

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus at baseline
  • Age \<18 years
  • Missing key clinical data precluding eligibility assessment or primary outcome evaluation
  • Refusal or inability to provide for the prospective component, where applicable
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
579 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Prospective Cohort

    Prospectively enrolled adult patients without diabetes at baseline undergoing partial, near-total, or total pancreatectomy at the study center.

  • Retrospective Cohort

    Retrospective cohort of adult patients without diabetes at baseline who underwent pancreatic surgery at the study center.

  • Ambispective Cohort

    Patients without diabetes at baseline with retrospective baseline data and prospective postoperative follow-up after pancreatic surgery.

06

What researchers measure

Primary outcomes

  1. Incidence of New-Onset Diabetes Mellitus After Pancreatectomy

    Incidence of new-onset diabetes mellitus in participants without diabetes at baseline according to the type of pancreatic resection.

    Time frame: Within 12 months after surgery

Secondary outcomes

  1. To assess the deterioration of glucose metabolism during post-pancreatectomy follow-up

    To assess the deterioration of glucose metabolism during post-pancreatectomy follow-up, defined as worsening of glycemic control parameters and/or the initiation or intensification of glucose-lowering therapy in patients without diabetes mellitus at baseline

    Time frame: From enrollment to the end of treatment at 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Data sharing plans have not yet been finalized. Any future sharing of de-identified individual participant data will be evaluated in accordance with institutional policies, ethical approvals, participant consent, and applicable data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2037, 130 months after the start.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 130 months is above that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 27, 2026
StartActual
Jul 20, 2026
Primary completionEst.
May 2037
CompletionEst.
May 2041
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07608055
Collaborators
European Foundation for the Study of Diabetes
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Jul 20, 2026
Primary completion
May 2037 (estimated)
Completion
May 2041 (estimated)
Last update
Sep 3, 2026

Study contacts

Teresa Mezza, MD, PhD
Contact
teresa.mezza@policlinicogemelli.it
06 30156664
Teresa Mezza
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion